TG Therapeutics, Inc. (TGTX)

♥ 404 Thanks from members

TG Therapeutics exhibits strong bullish momentum driven by surging Briumvi sales and upwardly revised 2026 revenue guidance, despite a Q2 earnings per share miss resulting from heavy manufacturing and pipeline investments.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: Michael S. Weiss Leadership: Michael S. Weiss (CEO) Leadership: Sean Power (CFO) Holder: Fidelity Management & Research Holder: BlackRock, Inc. Holder: Vanguard Group Briumvi Ukoniq Pipeline Therapeutics #TGTX stock #TG Therapeutics #Briumvi multiple sclerosis #NASDAQ TGTX #biotech stock